Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tenalisib
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Rhizen Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)
Details : Tenalisib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Triple Negative Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 03, 2024
Lead Product(s) : Tenalisib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Rhizen Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RP7214
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : Rhizen Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RP7214 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 16, 2021
Lead Product(s) : RP7214
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : Rhizen Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable